| __timestamp | Merck & Co., Inc. | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 11606000000 | 6795238 |
| Thursday, January 1, 2015 | 10313000000 | 7454247 |
| Friday, January 1, 2016 | 9762000000 | 10345862 |
| Sunday, January 1, 2017 | 9830000000 | 16984203 |
| Monday, January 1, 2018 | 10102000000 | 16187290 |
| Tuesday, January 1, 2019 | 10615000000 | 9299233.54 |
| Wednesday, January 1, 2020 | 8955000000 | 19232000 |
| Friday, January 1, 2021 | 9634000000 | 23611000 |
| Saturday, January 1, 2022 | 10042000000 | 26700000 |
| Sunday, January 1, 2023 | 10504000000 | 28215000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of major players is crucial. Merck & Co., Inc., a global leader, and Summit Therapeutics Inc., a smaller yet ambitious firm, offer a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023.
Merck's SG&A expenses have shown a steady trend, averaging around $10 billion annually, with a slight dip in 2020. This reflects a robust financial strategy, maintaining a consistent investment in operational efficiency and market presence. In contrast, Summit Therapeutics, with expenses averaging around $16 million, has seen a significant increase of over 300% from 2014 to 2023, indicating aggressive growth and expansion efforts.
This comparison highlights the diverse strategies within the pharmaceutical sector, where giants maintain stability while smaller firms push for rapid growth.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Jazz Pharmaceuticals plc
Summit Therapeutics Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Summit Therapeutics Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Wave Life Sciences Ltd. Trends and Insights
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.